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Introduction
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are 
an abundant family of nuclear RNA-binding proteins (RBP) 
that associate with nascent pre-mRNA transcripts,1 and have 
pleotropic roles in nucleic acid processing including alternative 
pre-RNA splicing and mRNA stability.2 The hnRNP-family 
protein structure is characterized by amine (N)-terminal RNA-
recognition motifs (RRMs) as well as RGG boxes (repeats of 
Arg-Gly-Gly tripeptides), which aid RNA binding and can be 
methylated to promote nuclear export.3,4
Of the hnRNPs, hnRNPA2 and splice variants (hnRNPs 
B1/A2b/B1b, hereafter referred to collectively as hnRNPA2), 
encoded by the HNRNPA2B1 gene, have generated significant 
interest due upregulation of expression in a number of cancers.5-10 
Cytoplasmic localization of hnRNPA2 is associated with gastric 
carcinogenesis8 and linked with a more aggressive disease pheno-
type of hepatocellular carcinoma.6,8
Functionally, hnRNPA2 has been shown to critically mediate 
the cancer cell phenotype through alternative splicing of key tran-
scripts involved in oncogenesis,7 tumor metabolism,11 invasive cell 
migration,12 and Epithelial to Mesenchymal Transition (EMT).13 
The cytoplasmic roles of hnRNPA2 protein in oncogenesis are 
not characterized, but will undoubtedly be elucidated through 
next generation sequencing-based analyses of the RBP-regulated 
transcriptome.14
In prostate cancer (PCa), there are increasing reports of over-
expression of RBPs,15 which are involved in a combinatorial con-
trol of alternative splicing.16 We previously characterized nuclear 
protein complexes in PCa cells associated with the RBP Sam68 
(KHDRBS1),17 which is overexpressed in clinical PCa,18,19 and 
identified associations with hnRNPA2 (as well as hnRNPs A1 
and L). Here, we explore the previously unreported function, 
expression, and localization of hnRNPA2 in PCa.
Results
hnRNPA2 mediates tumorigenesis and proliferation of PCa 
cells
To determine the role of hnRNPA2 in the tumorige-
nicity of PCa cells, we used RNAi to examine the colony 
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Introduction: The RNa-binding protein hnRNPa2 (HNRNPA2B1) is upregulated in cancer, where it controls alternative 
pre-mRNa splicing of cancer-relevant genes. cytoplasmic hnRNPa2 is reported in aggressive cancers, but is functionally 
uncharacterized. We explored the role of hnRNPa2 in prostate cancer (Pca). Methods: hnRNPa2 function/localization/
expression in Pca was determined using biochemical approaches (colony forming/proliferation/luciferase reporter assays/
flow cytometry/immunohistocytochemistry). Binding of hnRNPa2 within cancer-relevant 3′-UTR mRNas was identified by 
bioinformatics. Results: RNai-mediated knockdown of hnRNPa2 reduced colony forming and proliferation, while hnRNPa2 
overexpression increased proliferation of Pca cells. Nuclear hnRNPa2 is overexpressed in high-grade clinical Pca, and is also 
observed in the cytoplasm in some cases. ectopic expression of a predominantly cytoplasmic variant hnRNPa2-ΔRGG also 
increased Pca cell proliferation, suggesting that cytoplasmic hnRNPa2 may also be functionally relevant in Pca. consistent 
with its known cytoplasmic roles, hnRNPa2 was associated with 3′-UTR mRNas of several cancer-relevant mRNas including 
β-catenin (CTNNB1). Both wild-type hnRNPa2 and hnRNPa2-ΔRGG act on CTNNB1 3′-UTR mRNa, increasing endogenous 
CTNNB1 mRNa expression and β-catenin protein expression and nuclear localization. Conclusion: Nuclear and cytoplasmic 
hnRNPa2 are present in Pca and appear to be functionally important. cytoplasmic hnRNPa2 may affect the cancer cell phe-
notype through 3′-UTR mRNa-mediated regulation of β-catenin expression and other cancer-relevant genes.
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forming efficiency of PCa cells depleted of hnRNPA2 protein. 
In common PCa cells lines, including the highly metastatic 
PC3-M cell line, hnRNPA2 protein is stably expressed (Fig. 
S1A), and migrates as a doublet, representing the two common 
isoforms. The predominant isoform in PCa cells is hnRNPA2 
(bottom band) with the minor hnRNPB1 isoform (top band) 
expressed at very low levels. Following transfection with two 
different siRNA duplexes (si1 and/or si2), there was at least an 
~77% reduction in hnRNPA2 protein levels compared with the 
non-silencing (NSi) control duplex (Fig. 1A).
RNAi-mediated depletion of hnRNPA2 protein  in PC3-M 
cells resulted in an ~80% reduction in the colony forming ability of 
Figure 1. For figure legend, see page 3.
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Figure 1 (see previous page_. hnRNPa2 mediates tumorigenesis and proliferation of Pca cells. (A) Pc3-M cells were transfected with two siRNa duplex 
sequences to hnRNPa2 (si1 or si2), or a combination (siPool), or non-silencing (Nsi) control to final concentration of 25 nM. after 72 h, total cell lysates 
were harvested and subjected to western analysis with antibodies to hnRNPa2 and α-tubulin. Western analysis images shown are representative of 
three independent experiments, from which densitometric band quantitation was performed to calculate the mean relative normalized fold change in 
protein expression (shown in brackets). (B and C) colony forming ability of Pc3-M cells depleted of hnRNPa2 protein was assessed by direct cell count-
ing (B), and data from at least three independent experiments were used to calculate means ± sD % colony forming efficiency (cFe) (*P = 0.03; **P = 
0.008; ***P = 0.007). (D) Proliferation of Pc3-M cells depleted of hnRNPa2 protein was measured using WsT-1 proliferation reagent, and normalized to 
Nsi control. Data from at least three independent experiments (each with at least five technical replicates) were used to calculate the means ± se (*P = 
0.048; **P = 0.01; ***P = 0.02). (E) cell cycle distributions of Pc3-M cells depleted of hnRNPa2 protein were assessed using flow cytometry. Percentages 
of cells in the s-phase of cell cycle were estimated from their DNa content as read by propidium iodine. Data from at least three independent experi-
ments were used to calculate the means ± sD (*P = 0.03; **P = 0.03). (F) Proliferation of Pc3 cells transfected with 0.2 µg of plasmid DNa vector encoding 
ha-tagged wild-type (WT) hnRNPa2 was measured using WsT-1 proliferation reagent, and normalized to empty vector (eV) control. Data from at least 
three independent experiments with at least five technical replicates were used to calculate the means ± se (*P = 0.002). (G) cell cycle distributions of 
Pc3 cells transfected with 2 µg of plasmid DNa vector encoding ha-tagged WT hnRNPa2 were assessed using flow cytometry, and compared with eV 
control. Percentages of cells in the s-phase of cell cycle were estimated from their DNa content as read by propidium iodine. Data from at least three 
independent experiments were used to calculate the means ± sD (*P = 0.02). (all P values shown are for comparisons with control conditions).
Table 1. analysis of histopathological data for nuclear hnRNPa2 protein 
expression
Median histoscore (IQR) P value
BPh (n = 29) 100 (128)
P = 0.069*
Pca (n = 84) 135 (50)
Gleason grade 3 (n = 41) 85 (166)
P = 0.03**Gleason grade 4 (n = 19) 200 (173)
Gleason grade 5 (n = 24) 165 (226)
*Mann Whitney U-Test; **Jonkheere-Terpstra; (IQR = interquartile range).
the cells as compared with the non-silenced control (P < 0.05) (Fig. 
1B and C). In the light of published data for glioblastoma cells,7 we 
hypothesized that this observed reduction in tumorigenesis was as 
a result of a reduction in cell proliferation. To test this hypothesis, 
we employed WST-1 assays to examine for changes in the prolif-
eration of PC3-M cells depleted of hnRNPA2 with the two differ-
ent siRNA duplexes (si1 and/or si2). hnRNPA2-depleted PC3-M 
cells exhibited an ~40% reduction in cell proliferation as compared 
with the non-silenced control (P < 0.05) (Fig. 1D).
To determine whether the above reduction in cell proliferation 
reflected a delay in cell cycle progression, hnRNPA2-depleted 
PC3-M cells were subjected to cell cycle analysis. We observed 
a statistically significant reduction in the proportion of PC3-M 
cells in S-phase (P < 0.05) when depleted of hnRNPA2 as com-
pared with the non-silenced control (Fig. 1E), but we did not 
observe any other statistically significant changes in the propor-
tion of cells within other stages of the cell cycle (Fig. S1B).
To test whether overexpression of hnRNPA2 protein yielded 
reciprocal changes in cell proliferation and cell cycle profiles, 
HA-tagged hnRNPA2 was ectopically expressed in PC3 cells 
(Fig. 1F). Following transfection with HA-tagged hnRNPA2, we 
observed an average of a 2.5-fold increase in hnRNPA2 protein 
levels compared with the empty vector control (Fig. S1C). In PC3 
cells overexpressing hnRNPA2, cell proliferation was increased by 
55% (P = 0.002) over the empty vector control (Fig. 1F). This 
increase in proliferation was accompanied by a statistically signifi-
cant increase in the proportion of cells in S-phase (P = 0.02) (Fig. 
1G), but no other statistically significant changes in the proportion 
of cells in other stages of the cell cycle were observed (Fig. S1D).
We observed similar changes to cell proliferation in the 
LNCaP cell line as observed in the PC3 cells for both overexpres-
sion and RNAi-mediated knockdown of hnRNPA2 (Fig. S1E 
and F). However, there were no associated effects on cell cycle 
profiles (data not shown). Taken together, these data demonstrate 
that hnRNPA2 protein mediates tumorigenesis and proliferation 
of PCa cells, possibly via activity on S-phase of the cell cycle.
Expression of hnRNPA2 protein is upregulated in high-
grade PCa
In the light of reports of upregulation of hnRNPA2 protein 
expression in other cancers, we examined the expression and local-
ization of hnRNPA2 protein by immunohistochemistry, using a 
tissue microarray (TMA) of benign and malignant human pros-
tate biopsies. All TMA cores demonstrated hnRNPA2 nuclear 
immunoreactivity within basal and luminal epithelial cells (Fig. 
2A). Normality testing of Histoscores did not reveal normally 
distributed groups (P > 0.05), and therefore, further analysis was 
performed by non-parametric testing. There was a trend toward 
overexpression of nuclear hnRNPA2 protein in PCa as compared 
with BPH, which did not reach statistical significance (P = 0.067) 
(Table 1). Expression of nuclear hnRNPA2 expression was associ-
ated with increased pathological grade (P = 0.03) (Table 1 and Fig. 
2). Furthermore, in a subgroup analysis of high-grade (Gleason 
4 and 5) PCa, there was statistically significant upregulation of 
nuclear hnRNPA2 compared with low-grade (Gleason 3) PCa (P 
= 0.011), and BPH controls (P = 0.003).
Cytoplasmic hnRNPA2 is present in PCa cells and also 
drives cell proliferation
Consistent with published data for other solid organ tumors,6,8 
immunoreactivity for hnRNPA2 protein was also observed in the 
cytoplasm of some PCa cores (Fig. 3A). To test whether cytoplas-
mic hnRNPA2 protein is also functionally relevant in PCa, we 
employed an ectopic expression vector encoding an HA-tagged 
hnRNPA2 mutant containing a deletion (R191-G253) of the 
RGG domain (hnRNPA2-ΔRGG), which is exclusively expressed 
in the cytoplasm.4 Expression of HA-tagged hnRNPA2-ΔRGG 
was confirmed by western analysis using an anti-HA-specific anti-
body, which detected a band migrating at a slightly lower molecu-
lar weight than wild-type HA-tagged hnRNPA2 (Fig. 3B).
To verify the cytoplasmic localization of ectopically expressed 
hnRNPA2, PC3 cells were transiently transfected with 
expression vectors for HA-tagged wild-type hnRNPA2 and 
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Figure 2. expression of nuclear hnRNPa2 protein is upregulated in high-grade Pca. (A) Nuclear hnRNPa2 protein expression in clinical prostate samples. 
Representative images from hnRNPa2-immunostained sections for BPh (left panel), Gleason grades 3 (middle panel) and 5 (right panel). (Bar = 100 µm). 
(B) histoscore populations are graphically represented using a box and whisker plot, as these data are not normally distributed. statistical analysis 
revealed significant overexpression of nuclear hnRNPa2 protein in Gleason 4 and 5 Pca as compared with BPh controls (P = 0.03).
hnRNPA2-ΔRGG and localization of proteins was compared by 
indirect immunofluorescence using the anti-HA antibody (Fig. 
3C). Ectopically expressed HA-wild-type hnRNPA2 protein 
was predominantly present in the nuclei of PC3 cells, although 
was also detected at much lower levels in the cytoplasm (Fig. 
3C). In contrast and consistent with previously published data,4 
HA-hnRNPA2-ΔRGG was predominantly expressed in the 
cytoplasm with minimal nuclear localization.
To determine whether cytoplasmic hnRNPA2 is also func-
tionally relevant in PCa, PC3 cells transfected transiently with 
HA-tagged hnRNPA2-ΔRGG were subjected to WST-1 assays 
and flow cytometry (Fig. 3D). In PC3 cells overexpressing 
hnRNPA2-ΔRGG, cell proliferation was increased by 35% (P 
= 0.02) over the empty vector control (Fig. 3D). This increase 
in proliferation was accompanied by a statistically significant 
increase in the proportion of cells in S-phase (P = 0.04) (Fig. 
3E). Taken together, these data clearly demonstrate the presence 
of and function for cytoplasmic hnRNPA2 protein in PCa cells.
hnRNPA2 acts on the 3'-UTR of CTNNB1 mRNA result-
ing in an increase in β-catenin protein expression
The nuclear functions of hnRNPA2 in mediating the can-
cer cell phenotype via alternative pre-mRNA splicing are well 
described,7,11-13 however its cytoplasmic roles are uncharacter-
ized. In the cytoplasm, hnRNPA2 has been shown to stabilize 
expression of mRNAs encoded by SLC2A1 (GLUT1) via 3′-UTR 
binding.20 Hence, we reasoned that when localized to the cyto-
plasm in PCa, hnRNPA2 may stabilize and/or affect translation 
of PCa-relevant mRNAs, which mediate its functional effects on 
cell proliferation.
To test this hypothesis, we searched for the association of 
hnRNPA2 protein with 3′-UTRs of all UCSC genes using a 
previously published data set of hnRNPA2 transcriptome-wide 
binding sites in 293T cells.14 To identify potential biologi-
cal pathways altered by the binding of hnRNPA2 to 3′-UTR 
mRNAs, an enrichment analysis was performed on the gene list 
using the KEGG database21 (Table S1). We observed statistically 
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Figure 3. For figure legend, see page 6.
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6 RNa Biology Volume 11 Issue 6
significant enrichment for genes within “Pathways in Cancer” (n 
= 121/326; enrichment = 2.81-fold; FDR < 0.05), which includes 
a number of genes within PCa-relevant cell signaling pathways 
(Table S1). In particular, we identified a number of hnRNPA2 
binding sites within the 3′-UTR regions of mRNAs derived from 
CTNNB1 (which encodes β-catenin protein) (Fig. 4A).
In the light of growing evidence implicating the activity of 
the Wnt/β-catenin signaling pathway in PCa,22 we hypoth-
esized that the association of hnRNPA2 protein to the CTNNB1 
3′-UTR mRNA may have an effect on mRNA stability and/or 
translation. To test this hypothesis, we first examined the effects 
of ectopic hnRNPA2 expression on 3′-UTR-mediated mRNA 
stability and/or translation using a luciferase reporter assay. 
HEK293 cells were transiently transfected with expression vec-
tors for wild-type hnRNPA2 and hnRNPA2-ΔRGG together 
with a luciferase reporter containing the 3′-UTR of CTNNB1 
mRNA23 (Fig. 4B). Overexpression of both the wild-type and 
the cytoplasmic hnRNPA2-ΔRGG mutant resulted in a dose-
dependent increase in luciferase reporter activity with a maximal 
~2-fold enhancement in activity achieved above the stimulatory 
level in the absence of ectopic hnRNPA2 (P < 0.05).
To determine whether overexpression of hnRNPA2 protein 
also affected endogenous CTNNB1 mRNA transcript expres-
sion, HEK293 cells were transiently transfected with expres-
sion vectors for wild-type hnRNPA2 and hnRNPA2-ΔRGG 
(Fig. 4C). Overexpression of both wild-type hnRNPA2 and the 
hnRNPA2-ΔRGG mutant resulted in a statistically significant 
increase in expression of CTNNB1 over the empty vector control 
(P < 0.05) (Fig. 4C). To test whether an increase in mRNA expres-
sion correlated with an increase in β-catenin protein expression, 
whole cell lysates were subjected to western analysis using anti-
HA and anti-β-catenin antibodies to confirm overexpression of 
HA-tagged proteins and effects on β-catenin protein expression 
(Fig. 4D). Overexpression of both wild-type hnRNPA2 and the 
hnRNP-ΔRGG mutant resulted in a dramatic 2.3-fold and 2.2-
fold increase, respectively, in β-catenin protein expression over 
empty vector controls (Fig. 4D, left panel). These findings were 
confirmed in PC3 cells (Fig. 4D, right panel), although baseline 
β-catenin protein expression was lower than in HEK293 cells, 
and the fold changes observed were ~1.4-fold and ~1.2-fold for 
wild-type hnRNPA2 and hnRNP-ΔRGG, respectively.
Finally, we used indirect immunofluorescence to determine 
the localization of the increased β-catenin protein in PC3 cells 
following overexpression of hnRNPA2 and hnRNPA2-ΔRGG 
(Fig. 4E). In the absence of ectopic hnRNPA2 expression, 
β-catenin protein was predominantly localized to the cell mem-
brane, with some nuclear expression. Ectopic expression of both 
wild-type hnRNPA2 and the hnRNPA2-ΔRGG resulted in a 
statistically significant increase in nuclear expression of β-catenin 
protein (P < 0.05) (Fig. 4F). Taken together, our data demon-
strate that hnRNPA2 acts on the 3′-UTR of CTNNB1 mRNA 
resulting in an increase in CTNNB1 mRNA stability, β-catenin 
protein expression, and nuclear localization.
Discussion
Nuclear hnRNPA2 protein is overexpressed in cancer and 
has been shown to mediate the cancer cell phenotype through 
alternative pre-mRNA splicing.7,11-13 Cytoplasmic localization of 
hnRNPA2 is reported in aggressive cancers,6,8 although its spe-
cific functional role in cancer is not yet characterized. Here, we 
demonstrate overexpression of hnRNPA2 protein in high-grade 
PCa as enhanced hnRNPA2 immunoreactivity, which is in keep-
ing with data for other solid organ tumors.6,8 As the antibody to 
hnRNPA2 recognizes both the A2 and B1 isoforms of this protein, 
we were unable to determine the relative contributions of these two 
isoforms to overall protein expression by immunohistochemistry. 
However, by western analysis of human PCa cell lines, the A2 iso-
form appears predominant (Fig. S1A). Future evaluation of these 
isoforms in clinical PCa samples would be of interest.
Consistent with published data,7,13 we also demonstrate that 
PCa cells depleted of hnRNPA2 have diminished proliferative and 
tumorigenic potential. Additionally we report, for the first time, a 
reciprocal increase in cell proliferation through overexpression of 
a solely cytoplasmic hnRNP-A2-ΔRGG mutant in PCa cells. In 
keeping with the cytoplasmic functions of hnRNPs,2 we identified 
a novel role for hnRNPA2 protein in CTNNB1 mRNA 3′-UTR-
mediated mRNA stability, and expression and nuclear localization 
of β-catenin protein, where it is thought to exert its transcriptional 
effects to drive tumorigenesis.24 Although the mechanisms of 
β-catenin protein degradation are well-described, comparatively 
little is known about the regulation of its production.24 Consistent 
with our findings, others have shown that RBPs can modulate 
CTNNB1 mRNA metabolism and β-catenin protein expres-
sion.25-29 Although a previously published study did not identify 
a decrease in β-catenin protein expression in hnRNPA2-depleted 
cells,7 this may be due to functional redundancy as exemplified by 
Figure 3 (see previous page). cytoplasmic hnRNPa2 protein is expressed in clinical Pca and mediates proliferation of Pca cells. (A) Representative 
images from hnRNPa2-immunostained Pca sections demonstrating cytoplasmic and nuclear protein expression (left panel) and nuclear protein expres-
sion alone (right panel). (Bar = 100 µm). (B) Representative western analysis images of Pc3 cells transfected with 2 µg of plasmid DNa vectors encoding 
ha-tagged wild-type (WT) hnRNPa2 or hnRNPa2-ΔRGG or empty vector (eV) control using antibodies to ha tag and α-tubulin. (C) Representative indi-
rect immunofluorescence images of Pc3 cells transfected with 2 µg of plasmid DNa vectors encoding ha-tagged WT hnRNPa2 (left) or hnRNPa2-ΔRGG 
(right) and captured by confocal laser scanning microscopy using indirect immunofluorescence and antibody to ha tag (green) and a DaPI nuclear coun-
terstain (blue). (D) Proliferation of Pc3 cells transfected with 0.2 µg of plasmid DNa vector encoding ha-tagged hnRNPa2-ΔRGG was measured using 
WsT-1 proliferation reagent, and normalized to empty vector control. Data from at least three independent experiments with at least five technical 
replicates were used to calculate the means ± se (*P = 0.02). (E) cell cycle distributions of Pc3 cells transfected with 2 µg of plasmid DNa vector encoding 
ha-tagged hnRNPa2-ΔRGG were assessed using flow cytometry. Percentages of cells in the s-phase of cell cycle were estimated from their DNa content 
as read by propidium iodine. Data from at least three independent experiments were used to calculate the means ± sD (*P = 0.04). (all p-values shown 
are for comparisons with control conditions).
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Figure 4. For figure legend, see page 8.
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8 RNa Biology Volume 11 Issue 6
complex mRNA transcript cross- and auto-regulation by hnRNP 
paralogs.14,30 In cancer, where RBPs are typically overexpressed, the 
biological significance of this phenomenon is unclear.
There is increasing evidence for a greater importance of 
mRNA and protein metabolism in the quantitative control of 
gene expression.31 Conserved mRNA 3′-UTR cis-regulatory 
regions can influence polyadenylation, localization, stability, 
and translation under the control of trans-acting factors such as 
miRNAs and RBPs,32 and reprogramming of mRNA 3′-UTRs 
can affect cell phenotypes.33 Hence, in PCa, overexpression and 
cytoplasmic localization of hnRNPA2 protein may increase 
CTNNB1 mRNA stability and/or protein expression via direct 
3′-UTR binding, thereby contributing to cell proliferation.
Our KEGG analysis of a published transcriptome-wide foot-
print of hnRNPA221 revealed hnRNPA2 binding sites within 
the 3′-UTRs of several cancer-relevant genes. Although the spe-
cific functional consequences of these RBP-mRNA associations 
remain unclear, it is likely that hnRNPA2 protein is involved in 
3′-UTR-mediated mRNA stability and translation of a number 
of other cancer-relevant genes in addition to CTNNB1. Further 
transcriptome-wide mapping studies of hnRNPA2 binding sites 
in the context of specific PCa phenotypes and downstream func-
tional analyses are required to fully elucidate the role of this RBP 
in prostate tumorigenesis and PCa disease progression.
Materials and Methods
Antibodies, plasmids, and oligonucleotides
The following antibodies were used: anti-hnRNPA2B1 
(Abcam; DP3B3), anti-α-tubulin (TU-02, Santa Cruz 
Biotechnology) anti-β-catenin (C19220, BD Biosciences), anti-
HA (haemagglutinin)-Tag (6E2, Cell Signaling), anti-mouse 
IgG HRP-linked (7076, Cell Signaling), Alexa Fluor® 488 
anti-Mouse IgG (A-11001, Invitrogen). The following plasmids 
have been described previously: pcDNA3-HA-hnRNPA2- 
cDNA,34 pCAGPM-HA-hnRNPA2,35 pMiR-Report -3′-UTR- 
β-catenin.23 Sequences used to generate siRNA duplexes were as 
previously described12: si1 5′-GAAUUAUUUA AUAACAUUA-3′ 
and si2 5′-GAAGAGUAGU UGAGCCAAA-3′, and a non-
silencing control (# D-001810-01-20, Dharmacon) was also 
used. Sequences used to generate oligonucleotide primers for 
PCR were as follows: CTNNB1_F 5'-gctttcagtt gagctgacca-3' 
and CTNNB1_R 5'-caagtccaag atcagcagtc tc-3', CASC3_F 
5'-ggggttccag ttaatacaag tttc-3' and CASC3_r 5'-gccagctgta 
tttctcttct gag-3', and, ACTB_F 5'-attggcaatgagcggttc-3' and 
ACTB_R 5'-cgtggatgccacaggact-3'. Universal Probe Library 
(04683633001, Roche) short hydrolysis probes 21 (CTNNB1), 
84 (CASC3), and 11 (ACTB) were used for qPCR analysis.
Cell culture, DNA, and siRNA transfections
All cells were grown at 37 °C in 5% CO2. LNCaP (CRL-1740, 
ATCC), PC3 (CRL-1435, ATCC), and HEK293 (CRL-1573, 
ATCC) cells were maintained in RPMI-1640 medium (31870-
025, Life Technologies) with 2 mM L-glutamine (25030-024, 
Life Technologies), supplemented with 10% fetal bovine serum 
(FBS) (A15-101, PAA Laboratories). PC3-M cells were derived 
as previously described36 and maintained as above. Transfections 
with plasmid DNA were performed as detailed in the figure leg-
ends using Lipofectamine LTX (15338-100, Life Technologies) 
according to manufacturer’s instructions. Transfections with 
siRNA duplexes were performed as detailed in the figure legends 
using RNAiMax (13778-075, Life Technologies) according to 
manufacturer’s instructions. Data obtained from siRNA-medi-
ated silencing of hnRNPA2 were normalized to those from the 
non-silencing control (# D-001810-01-20, Dharmacon).
Western analysis
Whole cell lysis was performed in sample loading buffer (0.125 
M Tris pH 6.8, 2% SDS, 10% glycerol, 10% β-mercaptoethanol, 
and 0.01% bromophenol blue) prior to protein fractionation by 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) on 12% 
w/v Tris gels. Electrophoresed samples were electroblotted onto 
an Immobilon-P membrane (IPVH00010, Millipore) prior 
to western analysis. Antibody concentrations were as follows: 
anti-hnRNPA2B1 (1:1000), anti-HA (1:1000), anti-α-tubulin 
(1:1000). HRP-linked secondary antibody (1:2000) was used 
for signal detection using Amersham ECL Western Blotting 
Detection Reagent (RPN2232, GE Life Sciences). Densitometric 
assessment of protein bands from at least three independent 
experiments was performed using ImageJ (http://rsb.info.nih.
gov/ij/), and intensities used to calculate mean relative normal-
ized fold-change in protein expression.
Proliferation assays
Figure 4 (see previous page). hnRNPa2 acts on the 3′-UTR of cTNNB1 mRNa resulting in an increased β-catenin protein expression. (A) Ucsc Genome 
Browser showing transcript details for CTNNB1. custom track showing locations of hnRNPa2 binding sites in 293T cells.14 (B) heK293 cells were trans-
fected with either pMiR-report-β-catenin-3′-UTR or pMiR-report-empty vector and pRL-null reporters, and ha-tagged wild-type (WT) hnRNPa2 or 
hnRNPa2-ΔRGG (50 ng, 100 ng, or 200 ng) or empty vector (eV). after 48 h cells were harvested for luciferase activity analysis, and data normalized to 
activity of pRL-null (DNa transfection control) vector as well as pMiR-report-empty (luciferase expression control) vector. Data from at least three inde-
pendent experiments with at least three technical replicates were used to calculate the means ± se (*P = 0.001, **P = 0.02, ***P = 0.009, #P = 0.002, ##P = 
0.01). (C) heK293 cells transfected with 2 µg of plasmid DNa vectors encoding ha-tagged WT hnRNPa2 or hnRNPa2-ΔRGG. qRT-PcR was performed on 
cDNas from two independent experiments, and levels of CTNNB1 transcript expression were normalized to a mean of CASC3 and ACTB levels to obtain 
mean relative normalized fold change ± se (*P = 0.006, **P = 0.04). (D) heK293 (left panel) Pc3 (right panel) cells transfected with 2 µg of plasmid DNa 
vectors encoding ha-tagged WT hnRNPa2 or hnRNPa2-ΔRGG using antibodies to ha tag and β-catenin. Western analysis images shown are represen-
tative of three independent experiments, from which densitometric band quantitation was performed to calculate the mean relative normalized fold 
change in total β-catenin protein expression (shown in brackets). (E) Pc3 cells were transfected with 2 µg of plasmid DNa vectors encoding ha-tagged 
WT hnRNPa2 or hnRNPa2-ΔRGG and images captured by confocal laser scanning microscopy using indirect immunofluorescence and antibody to 
β-catenin (green) and a DaPI nuclear counterstain (blue). Indirect immunofluorescence images shown are representative of two fields of view, from 
which densitometric fluorescence quantitation was performed to calculate means relative normalized fold-change in β-catenin nuclear protein expres-
sion ± sD (all P values shown are for comparisons with control conditions).
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Proliferation assays were performed using the WST-1 cell pro-
liferation reagent (05015944001, Roche) as per manufacturer’s 
instructions. Briefly, 4000–10 000 cells were seeded into each well 
of a 96-well plates and grown to ~20–30% confluence prior to 
transfection with either siRNA or DNA as indicated above. After 
72 h, 10 μl WST-1 reagent was added to each well, mixed, and 
left to develop for 1 h before reading the absorbance at 450 nm 
(with reference wavelength at 650 nm) using SpectraMax Plus384 
Absorbance Microplate Reader (Molecular Devices). All data were 
normalized to either a non-silencing control or an empty vector 
control. Results shown are the means ± SEM of at least three inde-
pendent experiments with at least five technical replicates.
Colony forming assays
Cells were seeded at a density of 500 cells/well into 6-well 
plates. After 14 d, colonies were fixed in methanol for 20 min, 
stained with hematoxylin, photographed using GeneSnap v.1.0 
(Syngene), and counted. Percentage colony forming efficiency 
(CFE) was calculated as follows: Colonies counted/number of 
cells seeded × 100. Results shown are the means ± SD of at least 
three independent experiments.
Flow cytometry
For cell cycle analysis, cells harvested and re-suspended in 
PBS (phosphate-buffered saline) containing 2% FBS, permeabi-
lized with 1% Triton X-100, stained with 2.5 μg/μl propidium 
iodide (81845, Fluka), and treated with RNase (100 μg/ml), at 
least 10 000 cells were evaluated for each sample. Data were col-
lected and analyzed using CellQuest Pro software (337452, BD 
Biosciences) on a FACScan cytometer (337452, BD Biosciences). 
Percentages of cells in the different stages of the cell cycle were 
estimated from their DNA content as read by propidium iodine. 
Results shown are the means ± SD of at least three independent 
experiments.
Immunohistochemistry
Immunohistochemistry was performed using a tissue micro-
array (TMA) of 30 benign and 122 treatment-naive malignant 
prostate biopsies derived by transurethral resection (TUR), as 
previously described37 in accordance with ethical approval (Trent 
Multi-center Research Ethics Committee Ref: MREC/01/4/061). 
Anti-hnRNPA2 antibody was used at a concentration of 1:1200 
following optimization of antibody dilution on tissue blocks. 
hnRNPA2 nuclear immunoreactivity was scored blindly with 
shielding from clinical data using a modification of the weighted 
histoscore method:38 Histoscores were calculated from the sum 
of (1 × % cells staining weakly) + (2 ´ % moderately positive) + 
(3 × % cells staining strongly positive), with a maximum of 300. 
Consistent with previously published data,39 our TMA analysis 
failure was 26% due to technical issues (loss of cores, change 
in pathology). The final study included 84 PCa and 29 BPH 
(Benign Prostatic Hyperplasia) cores. The mean of the two his-
toscores obtained from assessment of immunoreactivity of two 
technical replicates was used for statistical analysis. All images 
were captured using ScanScope CS scanner (Aperio) and viewed 
using the Slidepath Gateway viewer (Leica).
Immunofluorescence
Cells were cultured in 6-well plates on glass coverslips, fixed 
with 100% methanol for 20 min at -20 °C, permeabilized in 0.1% 
Triton X-100, and blocked with 10% goat serum in PBS. Cells 
were incubated with the primary antibody and subsequently fluo-
rescent probe-linked secondary antibody. Finally, coverslips were 
mounted with Vectrashield Mounting Medium (H-1200, Vector 
Laboratories) containing DAPI (4’, 6-diamidino-2-phenylindole) 
DNA counterstain. All images were captured using confocal 
laser scanning microscopy (LSM510, Zeiss). Typically, 50–70% 
cell transfection efficiency was observed for tagged constructs. 
Densitometric assessment of cell fluorescence from two fields of 
view at x63 magnification was performed using ImageJ (http://
rsb.info.nih.gov/ij/), and intensities used to calculate means ± SD 
relative normalized fold-change in protein expression.
Bioinformatics
Publically available sequence read archive (SRA) files con-
taining transcriptome-wide binding sites for hnRNPA2B114 were 
uploaded to Galaxy40 using the EBI-SRA tool, and mapped to 
the human genome assembly hg18 using Bowtie2.41 Intervals 
overlapping with 3′-UTRs derived from University of California 
Santa Cruz (UCSC) known genes were intersected and uploaded 
into the UCSC Genome Browser.42 Enriched KEGG (Kyoto 
Encyclopedia of Genes and Genomes) pathways21 were identified 
by uploading the final gene list of transcripts with hnRNPA2 
binding sites within their 3′-UTRs to WebGestalt (WEB-
based GEne SeT AnaLysis Toolkit).43 Associations and testing 
of each pathway for gene enrichment was performed through 
the WebGestalt software with a hypergeometric test using the 
Bonferroni correction method for multiple testing. Pathways 
were deemed to be enriched if the ratio of enrichment over back-
ground was at least 2-fold and FDR < 0.05.
Luciferase reporter assays
HEK293 cells were seeded at a density of 2 × 104 cells/well in 
24-well plates. Cells were transfected with DNA as detailed in 
the figure legends. Firefly and Renilla luciferase assays were per-
formed using the Dual Luciferase Reporter Assay system (E1910, 
Promega) as per manufacturer’s instructions to give relative lucif-
erase activity. Results shown are the means ± SE of at least three 
independent experiments with three technical replicates.
RNA extraction, reverse transcription (RT), and quantita-
tive PCR (PCR)
Total RNA was extracted using the RNeasy Mini Kit (74104, 
QIAGEN) according to the manufacturer’s instructions. Reverse 
transcription of 1 μg of total RNA using the High-Capacity 
cDNA Reverse Transcription Kit (4368814, Applied Biosystems) 
according to the manufacturer’s instructions. qPCR was per-
formed on the 7500 Fast Real-Time PCR machine (Applied 
Biosystems, 4351106) using triplicate cDNA templates with 
the TaqMan Universal PCR Master mix (4304437, Roche 
Diagnostics) and Universal Probe Library set (04683633001, 
Roche) according to the manufacturer’s instructions. Reaction 
conditions were as follows: 20 s at 50 °C, 10 min at 95 °C, and 40 
cycles of 15 s at 95 °C and 1 min at 60 °C. Relative gene expres-
sion was determined by the 2-ΔΔCT method using SDS v1.4.2 
software (Applied Biosystems) using the mean of two validated 
endogenous control genes (CASC3 and ACTB) to ensure the 
reliability and reproducibility of observed effects. All data was 
normalized to the empty vector controls. Results shown are the 
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means ± SE of two independent experiments with three technical 
replicates.
Statistical analysis
The one-sample Kolmogorov–Smirnov test was used for 
assessment of the normality of clinical data, and Mann–Whitney 
U-test and Jonkheere–Terpstra test employed to identify differ-
ences between groups. For in vitro data, the one-tailed indepen-
dent sample T-Test was employed to identify differences between 
groups. All statistical tests were undertaken using SPSS v.19.0 
(SPSS, Inc.) and Prism v.6 (Graphpad) computer software with P 
< 0.05 taken to indicate statistical significance.
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